Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05387785

Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial

Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period, 2-Arm, 4-Sequence, Crossover Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ang-3070 in Subjects With Idiopathic Pulmonary Fibrosis Who Are Treatment-Naïve or Who Have Failed or Refused Standard of Care Treatment

Clinical Trial Summary

The purpose of this study is to assess safety and tolerability of once daily (QD) and twice daily (BID) dosing of ANG-3070 in subjects with idiopathic pulmonary fibrosis (IPF) who are treatment-naïve, refused therapy, or discontinued for any reason current standard of care with nintedanib or pirfenidone.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05387785
Study type Interventional
Source Angion Biomedica Corp
Contact Chantal Gosselin
Phone 857-378-4175
Email 3070IPF@angion.com
Status Not yet recruiting
Phase Phase 1
Start date June 2022
Completion date November 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04497831 - Morphine for Dyspnea in Pulmonary Fibrosis Phase 3
Recruiting NCT05119972 - Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF） Phase 1/Phase 2
Completed NCT01718990 - Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
Completed NCT00162760 - Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide Phase 2
Terminated NCT04589260 - TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis Phase 1
Completed NCT04069143 - A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327 Phase 1
Completed NCT03050255 - Short-term Effects of Supplemental Oxygen in Patients With IPF N/A
Terminated NCT02013700 - Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER) Phase 1
Active, not recruiting NCT04598919 - Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis Phase 1/Phase 2
Completed NCT03981094 - A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants Phase 1
Completed NCT02758808 - Pulmonary Fibrosis Foundation Patient Registry
Active, not recruiting NCT05938920 - Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Completed NCT02538536 - A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Completed NCT01371305 - STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Withdrawn NCT03720483 - Inhaled NAC in Treatment of IPF Phase 1/Phase 2
Recruiting NCT03478553 - The Genetics of Pulmonary Fibrosis
Recruiting NCT05975983 - Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03650075 - To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers Phase 1
Completed NCT03832946 - A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Completed NCT02874989 - Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial Phase 1